| AMGN |
Report |
Q2 2026 total revenue |
IN-LINE |
pred ~$9.18B vs. cons $9.15B |
MEDIUM |
| AMGN |
Report |
Q2 2026 non-GAAP EPS |
BEAT |
pred ~$5.32 vs. cons $5.22 |
MEDIUM |
| AMGN |
Report |
Q2 2026 Prolia + XGEVA sales |
MISS |
pred ~$1.00B vs. cons $1.04B |
MEDIUM |
| AMGN |
Guide |
FY2026 total-revenue guidance |
UNCHANGED |
guide ~$37.80B midpoint vs. cons $37.85B (FY2026) |
HIGH |
| AMGN |
Guide |
FY2026 non-GAAP EPS guidance |
UNCHANGED |
guide ~$22.40 midpoint vs. cons $22.45 (FY2026) |
HIGH |
| AMGN |
Guide |
FY2026 non-GAAP operating-margin guidance |
UNCHANGED |
guide ~45.5% midpoint vs. cons 45.5% (FY2026) |
HIGH |
| AMGN |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.3% |
— |
MEDIUM |
| AMGN |
Return |
5-day cumulative residual |
-4.1% (FOLLOW-THROUGH) |
A ~$5.32 EPS result versus $5.22 consensus is likely insufficient to offset a ~$1.00B denosumab result versus $1.04B consensus and unchanged $37.80B revenue / $22.40 EPS FY2026 guide versus $37.85B / $22.45B consensus; the lack of an out-period raise should prompt modest 2026-2027 estimate cuts. |
MEDIUM |